Enhanced anti-proliferative efficacy of epothilone B loaded with Escherichia coli Nissle 1917 bacterial ghosts on the HeLa cells by mitochondrial pathway of apoptosis

References

• Altaba R, Fojo T, Reed E, et al. Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr Pharm Des. 2002;8:1707–1712.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res. 2008;14:1618–1624.
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Coudert B, Isambert N, et al. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18(Suppl 5):v9–15.
   PubMed Web of Science ®Google Scholar
• Goodin S. Novel cytotoxic agents: epothilones. Am J Health Syst Pharm. 2008;65:S10–S15.
   PubMed Web of Science ®Google Scholar
• Mozzetti S, Martinelli E, Raspaglio G, et al. Gli family transcription factors are drivers of patupilone resistance in ovarian cancer. Biochem Pharmacol. 2012;84:1409–1418.
   PubMed Web of Science ®Google Scholar
• Rothermel J, Wartmann M, Chen T, et al. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol. 2003;30(3 Suppl 6):51–55.
   Web of Science ®Google Scholar
• Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009;63:201–212.
   PubMed Web of Science ®Google Scholar
• Oehler C, von Bueren AO, Furmanova P, et al. The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells. Neuro Oncol. 2011;13:1000–1010.
   PubMed Web of Science ®Google Scholar
• Diaz-Padilla I, Oza AM. Epothilones in the treatment of ovarian cancer. Future Oncol. 2011;7:559–568.
   PubMed Web of Science ®Google Scholar
• Zagouri F, Sergentanis TN, Chrysikos D, et al. Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review. Onco Targets Ther. 2015;8:2187–2198.
   PubMed Web of Science ®Google Scholar
• Hajam IA, Dar PA, Won G, et al. Bacterial ghosts as adjuvants: mechanisms and potential. Vet Res. 2017;48:37.
   PubMed Web of Science ®Google Scholar
• Kraśko JA, Žilionytė K, Darinskas A, et al. Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. Oncol Rep. 2017;37:171–178.
   PubMed Web of Science ®Google Scholar
• Langemann T, Koller VJ, Muhammad A, et al. The Bacterial Ghost platform system: production and applications. Bioeng Bugs. 2010;1:326–336.
   PubMedGoogle Scholar
• Ganeshpurkar A, Ganeshpurkar A, Pandey V, et al. N. Harnessing the potential of bacterial ghost for the effective delivery of drugs and biotherapeutics. Int J Pharma Investig. 2014;4:1–4.
   PubMedGoogle Scholar
• Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release. 2004;94:63–74.
   PubMed Web of Science ®Google Scholar
• Sonnenborn U, Schulze J. The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic. Microb Ecol Health Dis. 2009;21:122–158.
   Google Scholar
• Stritzker J, Weibel S, Hill FJ. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. J Med Microbiol. 2007;297:151–162.
   Web of Science ®Google Scholar
• Zhu W, Zhang Y, Liu X. Efficient production of safety-enhanced Escherichia coli ghosts bytandem expression of PhiX 174 mutant gene E and staphylococcalnuclease A gene. Microbiol Res. 2015;176:7–13.
   PubMed Web of Science ®Google Scholar
• Huang PS, Oliff A. Drug-targeting strategies in cancer therapy. Curr Opin Genet Dev. 2001;11:104–110.
   PubMed Web of Science ®Google Scholar
• Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab. 2010;11:129–141.
   PubMed Web of Science ®Google Scholar
• Crosasso P, Ceruti M, Brusa P, et al. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release. 2000;63:19–30.
   PubMed Web of Science ®Google Scholar
• Arias JL. Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem. 2011;11:1–17.
   PubMed Web of Science ®Google Scholar
• Paukner S, Kohl G, Jalava K, et al. Sealed bacterial ghosts-novel targeting vehicles for advanced drug delivery of water-soluble substances. J Drug Target. 2003;11:151–161.
   PubMed Web of Science ®Google Scholar
• Shin DH, Kwon GS. Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy. Int J Pharm. 2017;518:307–311.
   PubMedGoogle Scholar
• Kudela P, Paukner S, Mayr UB, et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett. 2008;262:54–63.
   PubMed Web of Science ®Google Scholar
• Kudela P, Koller VJ, Mayr UB, et al. Bacterial ghosts as antigen and drug delivery system for ocular surface diseases: effective internalization of Bacterial Ghosts by human conjunctival epithelial cells. J Biotechnol. 2011;153:167–175.
   PubMed Web of Science ®Google Scholar
• Stein E, Inic-Kanada A, Belij S, et al. In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases. Invest Ophthalmol Vis Sci. 2013;54:6326–6333.
   Google Scholar
• Kirschning CJ, Schumann RR. TLR-2: cellular sensor for microbial and endogenous molecular patterns. Curr Top Microbiol Immunol. 2002;270:121–144.
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–376.
   PubMed Web of Science ®Google Scholar
• Pellicciotta I, Yang CP, Venditti CA, et al. Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. Cancer Cell Int. 2013;13:33.
   PubMed Web of Science ®Google Scholar
• Rogalska A, Marczak A, Gajek A, et al. Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol In Vitro. 2013;27:239–249.
   Google Scholar
• Takai N, Ueda T, Nishida M, et al. PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells. Int J Mol Med. 2010;25:97–103.
   PubMed Web of Science ®Google Scholar
• Giorgi C, Baldassari F, Bononi A, et al. Mitochondrial Ca(2+) and apoptosis. Cell Calcium. 2012;52:36–43.
   PubMed Web of Science ®Google Scholar
• Rogalska A, Koceva CA, Jozwiak Z. Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chem Biol Interact. 2008;176:58–70.
   PubMed Web of Science ®Google Scholar
• Rogalska A, Marczak A. Epothilone B induces human ovarian cancer OV-90cell apoptosis via external pathway. Environ Toxicol Phar. 2015;39:700–712.
   PubMed Web of Science ®Google Scholar
• Gan PP, McCarroll JA, Byrne FL, et al. Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One. 2011;6:e21717.
   PubMed Web of Science ®Google Scholar